// App-Quantinova.ai

2542 : A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors.

Researchers

Presenter

  • Afshin Dowlati

Principal Investigators

  • Gordana Vlahovic

  • Yuying C. Hwang

  • John Rossi

  • Michael B. Bass

  • Gregory R. Friberg

  • Cheryl Ann Pickett-Gies

  • Ronald B. Natale

  • Erik Rasmussen

  • Indrajeet Singh

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CAAmgen, Inc., Thousand Oaks, CAAmgen Inc., Thousand Oaks, CA

  • Case Western Reserve University and University Hospitals, Cleveland, OH

  • Department of Molecular Sciences and Computational Biology, Amgen Inc., Thousand Oaks, CA

  • Oncology Clinical Development, Amgen Inc., Thousand Oaks, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Angiopoietin 1

  • Dynamic contrast-enhanced magnetic resonance imaging

Drug/Treatment

  • AMG 780

Outcome

  • Positive

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • NCT01137552

Sponsors

  • Amgen

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved